Brydøy M - Search Results

1

Normal tissue complication probability models in plan evaluation of children with brain tumors referred to proton therapy.

Stokkevåg CH, Indelicato DJ, Herfarth K, Magelssen H, Evensen ME, Ugland M, Nordberg T, Nystad TA, Hægeland C, Alsaker MD, Ulven K, Dale JE, Engeseth GM, Boer CG, Toussaint L, Kornerup JS, Pettersen HES, Brydøy M, Brandal P, Muren LP. Stokkevåg CH, et al. Among authors: brydoy m. Acta Oncol. 2019 Oct;58(10):1416-1422. doi: 10.1080/0284186X.2019.1643496. Epub 2019 Jul 31. Acta Oncol. 2019. PMID: 31364899

2

The effects of cancer and cancer treatments on male reproductive function.

Magelssen H, Brydøy M, Fosså SD. Magelssen H, et al. Among authors: brydoy m. Nat Clin Pract Urol. 2006 Jun;3(6):312-22. doi: 10.1038/ncpuro0508. Nat Clin Pract Urol. 2006. PMID: 16763643 Review.

3

Gonadal dysfunction and fertility problems in cancer survivors.

Brydøy M, Fosså SD, Dahl O, Bjøro T. Brydøy M, et al. Acta Oncol. 2007;46(4):480-9. doi: 10.1080/02841860601166958. Acta Oncol. 2007. PMID: 17497315 Review.

4

Estimated risk of radiation-induced cancer following paediatric cranio-spinal irradiation with electron, photon and proton therapy.

Stokkevåg CH, Engeseth GM, Ytre-Hauge KS, Röhrich D, Odland OH, Muren LP, Brydøy M, Hysing LB, Szostak A, Palmer MB, Petersen JB. Stokkevåg CH, et al. Among authors: brydoy m. Acta Oncol. 2014 Aug;53(8):1048-57. doi: 10.3109/0284186X.2014.928420. Epub 2014 Jul 14. Acta Oncol. 2014. PMID: 25017376

5

Nuclear maspin expression as a predictive marker for fluorouracil treatment response in colon cancer.

Hestetun KE, Brydøy M, Myklebust MP, Dahl O. Hestetun KE, et al. Among authors: brydoy m. Acta Oncol. 2015 Apr;54(4):470-9. doi: 10.3109/0284186X.2014.952386. Epub 2014 Sep 17. Acta Oncol. 2015. PMID: 25227897 Clinical Trial.

6

Linear energy transfer distributions in the brainstem depending on tumour location in intensity-modulated proton therapy of paediatric cancer.

Fjæra LF, Li Z, Ytre-Hauge KS, Muren LP, Indelicato DJ, Lassen-Ramshad Y, Engeseth GM, Brydøy M, Mairani A, Flampouri S, Dahl O, Stokkevåg CH. Fjæra LF, et al. Among authors: brydoy m. Acta Oncol. 2017 Jun;56(6):763-768. doi: 10.1080/0284186X.2017.1314007. Epub 2017 Apr 19. Acta Oncol. 2017. PMID: 28423966

7

Hearing loss before and after cisplatin-based chemotherapy in testicular cancer survivors: a longitudinal study.

Haugnes HS, Stenklev NC, Brydøy M, Dahl O, Wilsgaard T, Laukli E, Fosså SD. Haugnes HS, et al. Among authors: brydoy m. Acta Oncol. 2018 Aug;57(8):1075-1083. doi: 10.1080/0284186X.2018.1433323. Epub 2018 Jan 31. Acta Oncol. 2018. PMID: 29384420

8

Long-term serum platinum changes and their association with cisplatin-related late effects in testicular cancer survivors.

Hjelle LV, Gundersen POM, Hellesnes R, Sprauten M, Brydøy M, Tandstad T, Wilsgaard T, Fosså SD, Oldenburg J, Bremnes RM, Haugnes HS. Hjelle LV, et al. Among authors: brydoy m. Acta Oncol. 2018 Oct;57(10):1392-1400. doi: 10.1080/0284186X.2018.1473641. Epub 2018 May 18. Acta Oncol. 2018. PMID: 29775128

9

Rationale for combination of radiation therapy and immune checkpoint blockers to improve cancer treatment.

Dahl O, Dale JE, Brydøy M. Dahl O, et al. Among authors: brydoy m. Acta Oncol. 2019 Jan;58(1):9-20. doi: 10.1080/0284186X.2018.1554259. Epub 2019 Jan 11. Acta Oncol. 2019. PMID: 30632870 Review.

10

The pioneers behind immune checkpoint blockers awarded the Nobel Prize in physiology or medicine 2018.

Dahl O, Brydøy M. Dahl O, et al. Among authors: brydoy m. Acta Oncol. 2019 Jan;58(1):1-8. doi: 10.1080/0284186X.2018.1555375. Epub 2019 Jan 30. Acta Oncol. 2019. PMID: 30698061 Review. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

31 results

Search Page